Abstract
Antibiotic resistance (ABR) represents a critical global health challenge, posing significant risks to effective disease management. In recent years, the evolution of antibiotic-resistant pathogens has outpaced the development of new antibiotics, leading to increased mortality and prolonged hospital stays. This article explores novel drug formulations aimed at combating antibiotic resistance. Specifically, it discusses the use of combination therapies, nanomedicine, and alternative antimicrobial agents. These novel formulations enhance the efficacy of existing antibiotics and provide new pathways to overcome resistant strains. The article also reviews current research on antimicrobial peptides, bacteriophage therapy, and drug delivery systems that target resistant bacteria. By embracing innovative strategies in drug formulation, we can mitigate the impact of antibiotic resistance and improve clinical outcomes.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.